SIOX — Sio Gene Therapies Cashflow Statement
0.000.00%
Last trade - 00:00- $33.95m
- -$12.17m
- 22
- 39
- 77
- 43
Annual cashflow statement for Sio Gene Therapies, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -222 | -129 | -72.6 | -32.4 | -71.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 31.6 | 11.5 | 8.56 | -4.77 | 7.83 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.22 | -19.1 | -4.89 | -10.3 | 3.44 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -190 | -134 | -67.5 | -46.6 | -60.3 |
| Capital Expenditures | -4.28 | -0.202 | -0.255 | -0.398 | -0.695 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | 12.8 | 4.34 |
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4.28 | -0.202 | -0.255 | 12.4 | 3.65 |
| Financing Cash Flow Items | 0.324 | 1.89 | 0.148 | 0.121 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 136 | 87.1 | 41.5 | 73.6 | 1.44 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -58.2 | -47.3 | -26.2 | 39.4 | -55.3 |